id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-2525-0006,FDA,FDA-2016-E-2525,Determination of Regulatory Review Period for Purposes of Patent Extension; BRIVIACT INJECTION New Drug Application 205837,Notice,Determinations,2019-12-12T05:00:00Z,2019,12,2019-12-12T05:00:00Z,2020-02-11T04:59:59Z,2020-01-28T02:04:02Z,2019-26812,0,0,0900006484206a35
FDA-2016-E-2525-0005,FDA,FDA-2016-E-2525,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2019-11-01T04:00:00Z,2019,11,2019-11-01T04:00:00Z,,2019-11-01T17:17:45Z,,0,0,0900006484115ddb
FDA-2016-E-2525-0004,FDA,FDA-2016-E-2525,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-01-19T05:00:00Z,2017,1,2017-01-19T05:00:00Z,,2017-01-19T12:46:58Z,,0,0,0900006482484222
FDA-2016-E-2525-0003,FDA,FDA-2016-E-2525,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-09-26T04:00:00Z,2016,9,2016-09-26T04:00:00Z,,2016-09-26T16:20:07Z,,0,0,0900006482267de8
FDA-2016-E-2525-0001,FDA,FDA-2016-E-2525,"Patent Extension Application from Harness, Dickey & Pierce P.L.C. (on behalf of UCB Biopharma SPRL)",Other,Application,2016-08-24T04:00:00Z,2016,8,2016-08-24T04:00:00Z,,2016-08-24T16:51:35Z,,0,0,0900006482197dd2
FDA-2016-E-2525-0002,FDA,FDA-2016-E-2525,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-08-24T04:00:00Z,2016,8,2016-08-24T04:00:00Z,,2016-08-24T16:51:42Z,,0,0,0900006482197dd4